Mumbai, India (CU)_ The Indian drug regulator, the Drugs Controller General of India (DCGI), has approved phase II and III clinical trials of HGCO19, which is the first mRNA COVID-19 vaccine candidate in the nation. Under the COVID-19 suraksha mission, Gennova Biopharmaceuticals is developing the vaccine in collaboration with the Department of Biotechnology and the Biotechnology Industry Research Assistance Council (BIRAC).
According to the the statement from the federal ministry of science and technology…
